Here we go!

The idea of sicklesense is to provide a forum where the results of contemporary research into sickle cell disease can be made available, and where viewers can comment on and discuss the relevance of the findings. I will try and enliven the science with some additional facts, figures, thoughts and observations about sickle cell along the way.

Many of you will take hydroxycarbamide and some will derive considerable symptomatic benefit from this drug, but it is not a cure. Crises still occur and patients remain anaemic and jaundiced and, whats more, the response to treatment is varies greatly between patients. Why is that? Well Martin Steinberg, from Boston and his colleagues provide an elegant answer in the most recent edition of Blood.

Hydroxycarbamide works, at least partially, by increasing the amount of foetal haemoglobin (Hb F) inside red blood cells. Steinberg calculates that there needs to be at least 10pg of Hb F inside at least 70% of all the red cells if there is to be a dramatic and consistent reduction in sickling and all it’s consequences Unfortunately, although many patients who take hydroxycarbamide will manage to increase their Hb F level to 20 or 25% of their total haemoglobin, the Hb F is not evenly distributed among their red cells, some red cells may contain a lot, but the majority will contain much less than the critical 10pg/cell allowing sickling to continue unchecked. Steinberg makes the point that hydroxycarbamide will never be the sole answer because increasing the dose, to try and achieve sufficient concentrations of Hb F in a majority of red cells, would result in unacceptable toxicity from the drug. What is needed are other drugs, perhaps taken in combination with hydroxycarbamide, which will increase the Hb F in a pancellular distribution, that is to say, in all the individuals red cells.

Now in mice, who have been genetically engineered so that they have sickle cell disease, a drug which inactivates a particular gene (BCL11A), does result in a pancellular increase in Hb F at concentrations >10pg/red cell, the therapeutic target that Steinberg has identified. Whether the same would happen in humans is as yet unknown, but watch this space!

Fetal haemoglobin in sickle cell anaemia: a glass half full? Martin Steinberg, David Chui, George Dover, Paola Sebastiani & Abdulrahman Alsultan Blood. 2014;123(4):481-485.

And to finish, a history lesson.

Dr Africanus James Horton

Dr Africanus Horton was probably the first doctor to publish a description, in the medical literature, of sickle cell disease. In his medical magnum opus, published in London in 1874, “The Diseases of Tropical Climates and Their Treatment” he noted the association between recurrent episodes of pain, fever and anaemia and recognized that these attacks were more frequent in the rainy season. He did not look down a microscope and did not see the abnormal, sickled red cells characteristic of the condition, nor did he name it, that came later, but he may have been the first to describe the typical clinical manifestations of the disease.

Africanus Horton was born James Beale Horton in 1835, in the village of Gloucester, outside Freetown, Sierra Leone. He was the only one of eight siblings to survive childhood. His parents were freed, Igbo slaves, rescued by the Royal Navy on the notorious Middle Passage and landed in Freetown, far away from their homeland in SE Nigeria. Freetown had been established in 1792 by John Clarkson, an abolitionist from Nova Scotia, Canada, specifically as a haven for freed slaves, and during the 19th century thousands of African Americans, West Indians and Africans made their way there, some  with the help of the Sierra Leone Company, to start a new life.

Africanus was an exceptional boy and must have been spotted early on as a student of unusual talents. Aged 15 years his family moved to Freetown itself were he was initially educated by the Church Missionary Society and subsequently attended the Fourah Bay Institute.

Fourah Bay Institute

Fourah Bay Institute

Founded in 1827, this was the first new university in West Africa since the slow decline of Timbuktu after their defeat in 1591 by an invading Moroccan army. It had been intended that Africanus would pursue a career in the church as an Anglican missionary, but in the early 1850’s The British War Office was looking for bright boys (it would have to be boys!) to train as doctors and Africanus was awarded a scholarship in 1853, together with two others, Samuel Campbell and William Davies, to study medicine in the UK. He trained at Kings College Hospital, in South London, and then at the University of Edinburgh, qualifying with an MD in 1859, only the second African to qualify in medicine from a British medical school. What, I wonder, did he make of the cold and rain of Edinburgh? It was whilst a medical student that he took the name Africanus, an expression of pride in his ancestry and possibly of defiance in the face of prejudice. He is remembered by a plaque in Buccleugh Place in central Edinburgh.


After qualifying Africanus was commissioned into the British Army as an Assistant-Staff Sergeant and served throughout West Africa, in The Gambia, Ghana and Nigeria, seeing active service in the Ashanti wars of 1863 and 1873 and rising to the rank of Surgeon Major before he retired from army life in 1879, after 20 years aged 38.

His interests were wide and varied; in addition to medicine and science he was an early African Nationalist, countering prejudice with a seminal work, published in London in 1868, “West African Countries and Peoples; a Vindication of the African Races”, which put forward novel ideas for the development of self government in West Africa; and he was also a banker, gold mining entrepreneur and philanthropist, giving much of his wealth for the advancement of scientific training in West Africa. Africanus died suddenly in Freetown in 1883, aged only 48 years, and was forgotten for some eighty years, until the rise of the independence movements in the 1960’s when he was lauded as an early champion of African independence.


About rogerjamos

I am a consultant haematologist who has worked in Hackney, London, UK with patients who have sickle cell disease for many years. Knowledge is power; the hope is that this blog will empower patients by putting them in touch with contemporary research into sickle cell disease and facilitating informed discussion on the issues raised. Dr Roger Amos MA, MD, FRCPath
This entry was posted in Uncategorized and tagged , , . Bookmark the permalink.

6 Responses to Here we go!

  1. Lisa Rose says:

    It is refreshing that a doctor feels inspired to connect patients with research in an effort to increase empowerment and engagement. This is exactly how we feel and have made every effort to stay abreast with current research even with the limitations placed by “doctors only” organizations such as ASH. It can be quite daunting to obtain full length, peer reviewed articles; furthermore, interpreting them with limited understanding of construct, design and findings can pose significant barriers towards patient comprehension and application. Thank you for starting this blog. I look forward to following it, participating in dialogue, and referring others here as well!

  2. Okeli Okonye says:

    Blimey, you learn something new everyday! Who would’ve thought there needs to be 10pg of Hb F inside at least 70% of all red cells to reduce the level of sickling.

    • rogerjamos says:

      Truly amazing! The point was that until now it has not been clear what level of Hb F we should aim for, how we should measure it and what level would be sufficient to prevent most of the complications of sickle cell disease. Mainly, doctors have measured the total amount of Hb F in a persons blood taking hydroxycarbamide, expressed as a percentage. So, if a patients Hb F went up from 3.0% to 20.5% on treatment we said that was a good response and expected their sickle cell to improve dramatically. Often it did but sometimes there was no real improvement and that was a puzzle. We now know that the Hb F has to present in ALL the red cells (or at least 70% of them); in patients who did not respond, this is not the case and the Hb F is only present in a few red cells. We also know that the concentration of Hb F must be at least 10pg/red cell. This means that in future, when we are trying to work out whether a new treatment is likely to be any good or not, we know exactly what we should be aiming at.

  3. Bala says:

    Questions from Kamal

    How efficient is HbF in carrying oxygen in comparison to HbA?
    If HbF gene is fully activated would the resultant HbF suffice to keep the patient from transfusion dependency?

    Question from me
    How is retirement so far?

    • rogerjamos says:

      Next blog about HbF so watch this space! But briefly, HbF has a slightly higher affinity for oxygen than HbA to facilitate oxygen transfer from mother to baby across the placenta, but otherwise functions in a very similar way to HbA and individuals with 100% HbF are not transfusion dependent and clinically little affected. As for second question, I seem to be as busy as ever!

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s